Projects per year
Personal profile
Personal profile
Martyn A. Sharpe is a classically trained biochemist and bioenergeticist with a strong background in chemistry and the reactions of both reactive oxygen and nitrogen species. He has had more than a decade’s worth of experience in examining the cell proliferation/death mechanisms, and has examined the growth and characteristics of many different cell types including astrocytes, neurons and neuronal/astrocyte co-cultures.
Dr. Sharpe enjoys a large number of collaborations/friendships with scientists worldwide and has published papers with 85 co-authors over the last 15 years. He is often asked to participate in projects where there is an overlap of chemistry/cell physiology; especially in the areas of reactive oxygen/nitrogen species.
Dr. Sharpe switched from classical biochemistry/bioenergetics into related pathologies, especially of the brain, a decade ago following the death of his uncle from glioblastoma multiforme, soon after diagnosis. He has used the knowledge he acquired to develop drugs and drug delivery systems to target gliomas.
In addition to nanosyringes Sharpe & Baskin have been developing prodrugs to target gliomas that are based on their maturation by monoamine oxidase B (MAOB).
Martyn is deeply committed to neuro-oncology and is determined to develop a therapy to treat the 220,000 people, worldwide, who develop gliomas each year.
Research interests
Dr Sharpe main areas of research have been the following:
-Design, synthesis and testing in vitro and in vivo MAOB activated pro-drugs and retention dyes for the treatment of glioma.
-Development of targeted nanosyringes for chemotherapy
-Examination of the sensitivity of human brain cells, astrocytes and neuron’s, toward organomercury
-Development of assays for identifying specific lesions in DNA
Research Area Keywords
- Neurosciences
Free-text keywords
- Drug design
- Nanotechnology
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 1 Finished
-
American Brain Tumor Association Discovery Grant - Targeting mitochondria with a new class of glioma-specific chemotherapeutic agents
Sharpe, M. A. (PI) & Baskin, D. S. (CoI)
American Brain Tumor Association
7/1/11 → 9/30/12
Project: Non Profit
-
Advances in gene therapy for high-grade glioma: a review of the clinical evidence
Goldman, M. J., Baskin, A. M., Sharpe, M. A. & Baskin, D. S., 2024, In: Expert Review of Neurotherapeutics. 24, 9, p. 879-895 17 p.Research output: Contribution to journal › Review article › peer-review
2 Scopus citations -
Targeting the Leloir Pathway with Galactose-Based Antimetabolites in Glioblastoma
Sharpe, M. A., Ijare, O. B., Raghavan, S., Baskin, A. M., Baskin, B. N. & Baskin, D. S., Oct 17 2024, In: Cancers. 16, 20, 3510.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Acquisition of Immune Privilege in GBM Tumors: Role of Prostaglandins and Bile Salts
Sharpe, M. A., Baskin, D. S., Johnson, R. D. & Baskin, A. M., Feb 6 2023, In: International journal of molecular sciences. 24, 4, 3198.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells
Hambarde, S., Manalo, J. M., Baskin, D. S., Sharpe, M. A. & Helekar, S. A., Dec 2023, In: Scientific Reports. 13, 1, p. 19264 19264.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, S. A. (Inventor), Baskin, D. S. (Inventor), Sharpe, M. A. (Inventor) & Pichumani, K. (Inventor), Jun 23 2022, IPC No. A61N 2/ 12 A I, Patent No. US2022193436, Priority date Dec 31 2021, Priority No. US202117567101Research output: Patent